|
Market Closed -
Nasdaq
21:00:00 16/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 2.570 USD | -3.75% |
|
-26.78% | +80.99% |
| 10-15 | Edesa Biotech, Inc. Receives FDA IND Clearance For Phase 2 Clinical Study Of EB06 In Vitiligo | CI |
| 08-19 | Edesa Biotech Launches Public Offering of Common Shares, Warrants | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EDESA BIOTECH, INC. | Bio Therapeutic Drugs | -3.75% | -26.78% | +80.99% | +9.02% | -95.26% | 34.72M |  | |  |
- Stock Market
- Stocks
- EDSA Stock
- Charts Edesa Biotech, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
